Case Report: Trastuzumab deruxtecan in human epidermal growth factor receptor 2-mutated lung cancer with continuous renal replacement therapy.
Saved in:
| Title: | Case Report: Trastuzumab deruxtecan in human epidermal growth factor receptor 2-mutated lung cancer with continuous renal replacement therapy. |
|---|---|
| Authors: | Wu S; Center of Excellence, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China., Ke C; Neuroscience Medical Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China., Wei M; Center of Excellence, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, Guangdong, China. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Jan 07; Vol. 15, pp. 1722169. Date of Electronic Publication: 2026 Jan 07 (Print Publication: 2025). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2025.1722169 |
